J&J: to present progress on retinas
(CercleFinance.com) - Johnson & Johnson's Janssen pharmaceutical companies today announced that five company-sponsored presentations will be made at the annual meeting of the European Society of Retina Specialists (EURETINA), to be held in Amsterdam from 5 to 8 October.
The presentations will include data from two Phase 1 trials of the investigational gene therapy JNJ-81201887 (JNJ-1887), one in patients with geographic atrophy and severe age-related macular degeneration (AMD), and one in wet AMD.
In addition, new research highlighting descriptive analyses of trial populations, patient perspectives on the symptoms and impact of X-linked retinitis pigmentosa (XLRP) and comorbidities in patients with hereditary retinal dystrophy will also be shared.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
The presentations will include data from two Phase 1 trials of the investigational gene therapy JNJ-81201887 (JNJ-1887), one in patients with geographic atrophy and severe age-related macular degeneration (AMD), and one in wet AMD.
In addition, new research highlighting descriptive analyses of trial populations, patient perspectives on the symptoms and impact of X-linked retinitis pigmentosa (XLRP) and comorbidities in patients with hereditary retinal dystrophy will also be shared.
Copyright (c) 2023 CercleFinance.com. All rights reserved.